Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis

Phase 2

Conditions: Langerhans Cell Histiocytosis

Interventions: Drug: Cytarabine

First Posted Date: 2019-10-10

Last Posted Date: 2021-06-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 40

Registration Number: NCT04121819

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Liver Lymphoma
Mantle Cell Lymphoma

Interventions: Drug: Bendamustine
Drug: Acalabrutinib
Drug: Bendamustine Hydrochloride
Drug: Cytarabine
Biological: Rituximab

First Posted Date: 2019-10-04

Last Posted Date: 2024-12-10

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 360

Registration Number: NCT04115631

Locations: 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸
Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States

and more 501 locations

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

Interventions: Drug: KRT-232
Drug: Decitabine
Drug: Cytarabine

First Posted Date: 2019-10-03

Last Posted Date: 2024-03-22

Lead Sponsor: Kartos Therapeutics, Inc.

Target Recruit Count: 70

Registration Number: NCT04113616

Locations: 🇩🇪
University Hospital Jena, Jena, Germany
🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇧🇪
UZ Gent, Ghent, Belgium

and more 55 locations

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Phase 1

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Quizartinib
Drug: Fludarabine
Drug: Cytarabine
Drug: Idarubicin
Drug: glycosylated G-CSF

First Posted Date: 2019-10-02

Last Posted Date: 2022-03-14

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 63

Registration Number: NCT04112589

Locations: 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸
Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸
Institut Català D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain

and more 17 locations

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Placebo oral tablet
Drug: Quizartinib
Drug: Cytarabine
Drug: Idarubicin

First Posted Date: 2019-09-27

Last Posted Date: 2022-01-21

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 273

Registration Number: NCT04107727

Locations: 🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, Spain
🇪🇸
Hospital Clínico Universitario de Valladolid, Valladolid, Spain
🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain

and more 42 locations

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Ficlatuzumab

First Posted Date: 2019-09-24

Last Posted Date: 2020-03-31

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Registration Number: NCT04100330

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Phase 2

Recruiting

Conditions: MDS
AML

Interventions: Drug: CPX-351
Drug: Daunorubicin
Drug: Cytarabine
Drug: Azacitidine

First Posted Date: 2019-08-19

Last Posted Date: 2023-10-11

Lead Sponsor: GWT-TUD GmbH

Target Recruit Count: 150

Registration Number: NCT04061239

Locations: 🇦🇹
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
🇩🇪
Universitätsklinikum Augsburg, Augsburg, Germany
🇩🇪
Klinikum Frankfurt (Oder) GmbH, Frankfurt, Germany

and more 25 locations

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Recurrent Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Refractory Acute Myeloid Leukemia
Refractory High Risk Myelodysplastic Syndrome
High Risk Myelodysplastic Syndrome
Recurrent High Risk Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Idarubicin
Drug: Quizartinib

First Posted Date: 2019-08-07

Last Posted Date: 2024-12-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04047641

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Phase 3

Recruiting

Conditions: Lymphoblastic Lymphoma, Childhood

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: 6-Mercaptopurine
Drug: Methotrexate
Drug: Doxorubicin
Drug: PEG asparaginase
Drug: Ifosfamide
Drug: Vincristine
Drug: Prednisone
Drug: Prednisolone
Drug: Thioguanine
Drug: Vindesine

First Posted Date: 2019-08-02

Last Posted Date: 2024-07-10

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 683

Registration Number: NCT04043494

Locations: 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷
Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪
UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium

and more 219 locations

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Solid Tumors
Neuroblastoma

Interventions: Drug: Idasanutlin
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Topotecan
Drug: Cytarabine
Drug: Intrathecal Chemotherapy

First Posted Date: 2019-07-23

Last Posted Date: 2024-12-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT04029688

Locations: 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸
Arnold Palmer Hosp-Children, Orlando, Florida, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy